Cephalosporin-based prodrug

Cephalosporin-based prodrug refers not to a single defined molecular target or receptor, but to a **prodrug strategy or motif** where a cephalosporin (β-lactam) moiety is covalently linked to another drug or payload (e.g., fluoroquinolones like ciprofloxacin, NO donors). These prodrugs are designed to be selectively activated by bacterial enzymes, especially β-lactamases, which are frequently expressed in resistant bacteria. Upon encountering β-lactamase, the cephalosporin ring is cleaved, releasing the active drug preferentially at the site of resistant infection. This targeted approach increases drug selectivity, minimizes toxicity to commensal bacteria, and can overcome certain forms of antibiotic resistance. “Cephalosporin-based prodrug,” however, is not a molecular “target,” but rather an engineered drug form that exploits the presence of natural bacterial targets (e.g., β-lactamase enzymes and penicillin-binding proteins) for targeted drug release[3][4][5]. **Note:** The phrase “Cephalosporin-based prodrug” is not a canonical protein, enzyme, or receptor, and thus is not a true “therapeutic target.” Rather, it describes a drug delivery strategy. For structured target databases, this entry is best flagged as incorrect for molecular target curation.

Other names

Cephalosporin prodrugCephalosporin-based prodrugβ-lactamase-activated cephalosporin prodrugcephalosporin–ciprofloxacin conjugatecephalosporin–NO donor prodrug

β-lactamase-triggered cleavage releases active drug (such as ciprofloxacin, NO donor) at the site of β-lactamase-expressing bacteria[3][4][5]